Denver Health and Hospital Authority
Denver, Colorado, 80204, United States
Location contact
Ivor S Douglas, MD
PRINCIPAL_INVESTIGATOR
Terra Miller, MSN, RN
CONTACT
NCT Number: NCT06669403
OPT101-100-40 is a multicenter, randomized, placebo-controlled, multiple-ascending-dose, sequential-group, investigator- and participant-blinded, sponsor-unblinded, study of OPT101 vs placebo when administered for up to 4 days to patients admitted to the hospital for treatment of Community Acquired Pneumonia (CAP) with sepsis.
This study will be performed in patients with Community Acquired Pneumonia (CAP) with Sepsis, who are 18 years or older to evaluate the safety and tolerability of OPT101 in a population with elevated levels of pathologic CD40.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Phase 1
Denver, Colorado, 80204, United States
Ivor S Douglas, MD
PRINCIPAL_INVESTIGATOR
Terra Miller, MSN, RN
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
AND at least 1 of the following:
Exclusion criteria
-
OPT101, is a 15-mer peptide derived from the sequence of mouse CD40L and was designed to target CD40-mediated inflammation. On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.
0.9% Sodium Chloride Injection USP, Placebo. On the day of administration, a 50mL IV bag containing saline (0.9% Sodium Chloride Injection USP) which will serve as the placebo will be administered via intravenous (IV) infusion over 120 minutes.
Other names: Placebeo
Time frame: 30 days
Treatment emergent adverse events will be recorded and assessed by CTCAE v4.0
Time frame: 30 days
SAEs will be recorded and assessed by CTCAE v4.0
Time frame: 30 days
Time frame: 30 days
Recorded as an adverse event
Time frame: 30 days
Serum concentrations of OPT101 to determine AUCO-24
Time frame: 30 days
Serum concentrations of OPT101 to determine Cmax
Time frame: 30 days
Serum concentrations of OPT101 to determine Tmax
Time frame: 30 days
Serum concentrations of OPT101 to determine t1/2
Time frame: 30 days
Serum concentrations of OPT101 to determine Vz/F
Time frame: 30 days
Pneumonia Severity Index (PSI) predicts the need for hospitalization for people with Community Acquired Pneumonia (CAP). Patients are ranked by Risk Class (I , II, III, IV or V). Patients with CAP categorized as Risk Class of I and II can be treated at home. Patients with CAP categorized as Risk Class III may be treated at home or may require a short hospital stay. Patients with CAP categorized as Risk Class of IV and V require hospitalization.
Time frame: 30 days
SOFA grading, minimum value is 0 (normal) and maximum value is 4 (highest degree of dysfunction/failure). The higher the score, the worse the outcome.
Time frame: 30 days
CRS is graded from Grade 1 to Grade 4. Grade 1 is the best outcome and Grade 4 is the worst outcome in terms of change in degree of sepsis. CRS parameters used for grading include fever, hypotension and hypoxia.
Time frame: 30 days
Quantitation of Th40 to Treg ratio
Time frame: 30 days
Quantitation of peripheral blood B cells
Time frame: 30 days
Quantitation of macrophages
Time frame: 30 days
Quantitation inflammatory biomarkers
Time frame: 30 days
Quantitation of Th40 cells,
Contact information is provided by the study sponsor or research team.
Lisa M Boswell, MS
CONTACT
Marc L Giles, BS
CONTACT
Op-T LLC
Industry
A Phase 1b Study to Assess the Safety, Tolerability and Pharmacokinetics of OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07109310
Acute Respiratory Distress Syndrome, Community Acquired Pneumonia
View Trial DetailsNCT04612413
Biliary Tract Diseases, Cholangitis Acute
Brussels, Belgium
View Trial DetailsNCT06516601
ARDS, Human, Community-Acquired Infections
Trieste, TS, Italy
View Trial DetailsNCT04724044
Biomarkers, Community-Acquired Infections
Athens, Greece
View Trial Details